The Prognostic Value of Peripheral Inflammatory Cell Ratios in Patients with Cervical Cancer After Radiotherapy

Ruizhe Xu (✉ andyxurz@sina.com)  
Second Affiliated Hospital of Soochow University  
https://orcid.org/0000-0002-2907-4455

Haiyan Lu  
Second Affiliated Hospital of Soochow University

Qi Guo  
Second Affiliated Hospital of Soochow University

Jianjun Qian  
Second Affiliated Hospital of Soochow University

Qihong Fan  
Second Affiliated Hospital of Soochow University

Peifeng Zhao  
Second Affiliated Hospital of Soochow University

Ye Tian  
Second Affiliated Hospital of Soochow University

Research

Keywords: neutrophil to lymphocyte ratio, platelet to lymphocyte ratio, cervical cancer, prognostic biomarkers, radiotherapy

Posted Date: November 2nd, 2021

DOI: https://doi.org/10.21203/rs.3.rs-1009848/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Introduction: This study aimed to explore the values of the neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) as prognostic biomarkers in patients with cervical cancer.

Methods: In total, 172 cervical cancer patients treated with radiotherapy between January 2014 and December 2017 were retrospectively identified. We calculated the NLR and PLR and determined their cut-off points, known prognostic factors, and the association of these factors with overall survival (OS).

Results: The median follow-up period was 59 months (range 1–91 months, 95% confidence interval 53–63 months). The 3- and 5-year OS rates of patients who received postoperative adjuvant radiotherapy were 86.7% and 79.7%, respectively, while the 3- and 5-year OS rates of patients who received radical radiotherapy were 70.2% and 61.6%, respectively. Univariate analysis identified that OS was significantly correlated with tumor diameter, pelvic lymph node status, the NLR and PLR before radiotherapy, past diabetes, International Federation of Gynecology and Obstetrics (FIGO) stage, the purpose of radiotherapy, pathology type, and the OS rate (all \( P < 0.05 \)). On multivariate analysis, the PLR before radiotherapy, past diabetes, FIGO stage, and pathology type were independently associated with OS (all \( P < 0.05 \)).

Conclusions: The NLR and PLR before radiotherapy are correlated with the prognosis of cervical cancer. Furthermore, the PLR before radiotherapy is an independent risk factor related to OS.

Introduction

Cervical cancer is one of the most common malignant tumor that threatens women's health. The incidence and mortality rate of cervical cancer are ranked fourth among malignancies in women, and women in developing countries are particularly vulnerable.[1–2] Radiotherapy is one of the most important treatment methods for cervical cancer.[3] At present, the prognosis of patients with cervical cancer mainly depends on the International Federation of Gynecology and Obstetrics (FIGO) stage.[4–6] However, recent studies have found that chronic inflammation plays an important role in cancer cell proliferation, angiogenesis, and immunosuppression and is related to the prognosis of patients with cancer.[7] Pertinently, the ratios of peripheral blood neutrophils to lymphocytes (NLR) and of platelets to lymphocytes (PLR) are important prognostic indicators related to systemic inflammatory response.[8] A series of studies have shown that the NLR and PLR values can be used as biomarkers for predicting the prognosis of patients with malignant tumors, including non-small cell lung, liver, gastric, colorectal, and pancreatic cancers.[9–13] However, there are few studies concerning the prognostic significance of the NLR and PLR in cervical cancer. Therefore, this study evaluates the prognostic value of the NLR and PLR in peripheral blood before radiotherapy to provide a reference for clinical work.

Methods
Patients

A total of 172 patients with cervical cancer who presented to our department between January 2014 to December 2017 were included in this study. Their clinical characteristics are listed in Table 1. Approximately 38.95% of patients received radical radiotherapy, while 58.72% of patients received postoperative assistance radiotherapy. We reviewed records related to treatment, complete blood cell counts before radiotherapy, and death. The last follow-up was June 15, 2021. A total of 37 patients died during the follow-up period.
Table 1
Clinicopathological characteristics of 172 patients with cervical cancer who underwent radiotherapy

| Characteristic                  | No. of patients (%) | Characteristic                  | No. of patients (%) |
|--------------------------------|---------------------|--------------------------------|---------------------|
| Age, years                     |                     | Tumor size                     |                     |
| ≥60                            | 47 (27.3)           | ≥4 cm                          | 87 (50.6)           |
| <60                            | 125 (72.7)          | <4 cm                          | 62 (36)             |
|                                |                     | Unknown                         | 23 (13.4)           |
| Pelvic lymph node              | 63 (36.6)           | FIGO stage                      | 124 (72.1)          |
| Positive                       | 98 (57)             | I–II                           | 31 (18.0)           |
| Negative                       | 11 (6.4)            | III                            | 12 (7.0)            |
| Unknown                        |                     | IV                             | 5 (2.9)             |
| Past diabetes                  | 9 (5.2)             | Previous hypertension           | 32 (18.6)           |
| Yes                            | 160 (93.0)          | Yes                            | 137 (79.7)          |
| No                             | 3 (1.7)             | No                             | 3 (1.7)             |
| Unknown                        |                     | Unknown                         |                     |
| The purpose of radiotherapy    | 67 (38.95)          | Pathological type               | 153 (89.0)          |
| Radical                        | 101 (58.72)         | Squamous cell carcinoma         | 10 (5.8)            |
| Postoperative assistance       | 4 (2.33)            | Adenocarcinoma                  | 8 (4.7)             |
| Unknown                        |                     | Other                           | 1 (0.6)             |
|                                |                     | Unknown                         |                     |
| NLR before radiotherapy        | 29 (16.9)           | PLR before radiotherapy         | 37 (21.5)           |
| High NLR (>4.33)               | 98 (57)             | High PLR (≥200.47)              | 90 (52.3)           |
| Low NLR (<4.33)                |                     | Low PLR (<200.47)               |                     |

NLR, neutrophil to lymphocyte ratio; PLR, platelet to lymphocyte ratio; FIGO, International Federation of Gynecology and Obstetrics

**NLR and PLR**

Peripheral venous blood was collected from patients before radiotherapy. The NLR and PLR were calculated as follows: NLR = neutrophil count / lymphocyte count and PLR = platelet count / lymphocyte count. Receiver operating characteristic (ROC) curves were used to determine the optimal critical value of
the NLR and PLR before radiotherapy. Patients were divided into a low NLR group, high NLR group, low PLR group, and high PLR group for analysis.

**Statistical analyses**

The endpoint of this study was overall survival (OS). The independent sample t-test or $\chi^2$ test was used to test the difference between continuous and categorical variables. The best cut-off values for the NLR and PLR were evaluated using ROC survival curve analysis. To investigate the relationships between the NLR or PLR and prognosis of cervical cancer, univariate and multivariate Cox regression models were used. Significance was defined as $P<0.05$. Statistical analyses were performed with SPSS 26.0 (IBM, Chicago, IL, USA).

**Results**

**Patient characteristics**

In total, 172 patients with cervical cancer who received radiotherapy were included in this study, of whom 127 had NLR and PLR values evaluated before radiotherapy. The median age of the entire group at diagnosis was 49 years (range 29–88 years). Patients' characteristics are shown in Table 1.

**Overall survival**

The median survival time of all patients was 59 months (95% CI: 53–63 months). At the end of follow-up, 32 patients were lost and 37 died. The 3- and 5-year OS rates of patients who received postoperative adjuvant radiotherapy were 86.7% and 79.7%, respectively. The 3- and 5-year OS rates of patients who received radical radiotherapy were 70.2% and 61.6%, respectively (Fig. 1).

**Univariate and multivariate analyses**

Tumor diameter, pelvic lymph node status, the NLR before radiotherapy, the PLR before radiotherapy, past diabetes, FIGO stage, the purpose of radiotherapy, and pathology type were all significantly correlated with the OS rate of patients ($P<0.05$). These parameters were also included in the multivariate analysis, which showed that the PLR before radiotherapy, past diabetes, FIGO stage, and pathology type were the factors that significantly affected OS rate ($P<0.05$), as shown in Table 2.
Table 2
Univariate and multivariate analysis of the impact of clinical factors on overall survival

| Clinical parameter                  | Univariate analysis | COX multivariate analysis |
|------------------------------------|---------------------|---------------------------|
|                                    | X²  | P       | HR   | 95% CI   | P   |
| Tumor size                         | 4.878 | 0.027  |      |          |     |
| Pelvic lymph node metastasis       | 15.347 | 0.000  |      |          |     |
| age                                | 3.369 | 0.066  |      |          |     |
| Pelvic lymph node metastasis       | 11.997 | 0.001  |      |          |     |
| PLR before radiotherapy            | 10.106 | 0.001  | 0.079 | 0.012–0.534 | 0.009 |
| Previous hypertension              | 3.504 | 0.061  |      |          |     |
| Past diabetes                      | 5.338 | 0.021  | 22.934 | 2.276–231.048 | 0.008 |
| FIGO stage                         | 39.014 | 0.000  | 2.837 | 1.325–6.077 | 0.007 |
| The purpose of radiotherapy        | 6.258 | 0.012  |      |          |     |
| Pathological type                  | 7.777 | 0.020  | 3.459 | 1.590–7.525 | 0.002 |

FIGO, International Federation of Gynecology and Obstetrics; HR, Hazard ratio; CI, confidence interval; PLR, platelet to lymphocyte ratio

Determination of NLR and PLR cut-off values

The range of the NLR was 0.55–19.80. The ROC curve of the NLR for cervical cancer prognosis was plotted according to the patient’s NLR value and survival time. The area under curve (AUC) was 0.649, and the 95% confidence interval (CI) was 0.528–0.770 (Fig. 2A). The boundary value of the NLR for predicting tumor prognosis was 4.33. The sensitivity was 48.1%, and the specificity was 84.0%. The range of the PLR was 4.71–460. The ROC curve of the PLR for cervical cancer prognosis was similarly plotted according to the PLR value and survival time. The AUC was 0.705, and the 95% CI was 0.600–0.811 (Fig. 2B). The boundary value of the PLR for predicting tumor prognosis was 200.47. The sensitivity was 59.3%, and the specificity was 79.0%.

Correlation between the NLR or PLR before radiotherapy and prognosis of patients

All patients were divided into two groups according to the critical value of NLR: patients with NLR >4.33 were included in the high NLR group (29 cases) and patients with NLR <4.33 in the low NLR group (98 cases). The 3-year OS rates of the high and low NLR groups were 60.7% and 86.3%, respectively. The 5-year OS rates of the high and low NLR groups were 51.7% and 83.3%, respectively (x² value 11.997, P=0.001). The survival curve is shown in Fig. 3A. According to the critical value of the PLR, all patients...
were divided into two groups: a high PLR group with PLR >200.47 (37 cases) and a low PLR group with PLR <200.47 (90 cases). The 3-year OS rates of the high and low PLR groups were 61.1% and 89.0%, respectively. The 5-year OS rates of the high and low PLR groups were 57.9% and 83.8%, respectively (χ² value 10.106, \( P=0.001 \)). The survival curve is shown in Fig. 3B.

**Correlation between peripheral blood NLR and FIGO stage**

The peripheral blood NLR values of the 127 patients with cervical cancer were included in a box diagram according to the FIGO stage (Fig. 4). Phases I–II and III–IV were divided into early and late stages, respectively. The average NLR was 2.859 in the early stage (95% CI 2.386–3.333) and 4.761 in the late stage (95% CI 3.540–5.981). There was a significant difference between the two phases (\( P=0.005 \)). The NLR value of peripheral blood was higher when the FIGO stage was more advanced.

**Discussion**

FIGO stage typifies tumor progression according to the results of clinical and imaging examinations, and this is an important means for prognosis prediction of patients with cervical cancer.[14–15] Recent studies have shown that inflammation plays an important role in the occurrence and development of cervical cancer. Hematological markers related to inflammation in complete blood cell count may help in the evaluation of the prognosis of patients.[16]

Inflammatory response is caused by inflammatory cells and a series of inflammatory mediators. Chronic inflammation is an important cause of immunosuppression in the tumor microenvironment. Inflammatory cells and cytokines or chemokines are involved in almost every step of tumor development. [16] Inflammatory response caused by tumors can lead to hematological changes, including relative neutrophilia, thrombocytosis, and lymphocytopenia. Therefore, patients with high NLR and PLR usually have severe systemic inflammatory responses, poor antitumor activities, and strong tumor invasiveness. Moreover, assessment of the NLR and PLR has the advantages of low cost, simple operation, and high repeatability.[8] Several studies have shown that the NLR and PLR can be used to predict the prognosis of patients with malignant tumors.[10–13] Such indicators have also been proven to be clinically relevant for cervical cancer.[9] Lu et al. [17] analyzed the prognosis of 120 patients diagnosed with cervical cancer and found that the systemic immune inflammation index influences patient survival and that the NLR and PLR are important factors that affect the OS rate. Zhang et al. [18] also found the NLR was an independent prognostic indicator of progression-free survival (PFS) of patients with cervical cancer. Consistent with previous studies, this study confirmed that such indicators can be used to predict the prognosis of patients with cervical cancer. The results of this study showed that the survival times of the high NLR and PLR groups were significantly lower than those of the low NLR and PLR groups. The 3-year OS rates of the high and low NLR groups were 60.7% and 86.3%, respectively. The 5-year OS rates of the high and low NLR groups were 51.7% and 83.3%, respectively (χ² value 11.997, \( P=0.001 \)). The 3-year OS rates of the high and low PLR groups were 61.1% and 89.0%, respectively. The 5-year OS rates of the high and low PLR groups were 57.9% and 83.8%, respectively (χ² value 10.106, \( P=0.001 \)). Univariate analysis
showed that both the NLR and PLR before radiotherapy were factors that were significantly associated with the prognosis of patients with cervical cancer. However, multivariate analysis showed that the NLR before radiotherapy was not an independent risk factor for the prognosis of patients with cervical cancer. The reason may be that the NLR value is significantly affected by the tumor stage (Fig. 4). The later the FIGO stage the more serious the systemic inflammatory response and the higher the NLR in peripheral blood.

This paper has the following limitations. First, this was a retrospective study. Some information were missing or inaccurate, which may have introduced bias. Some patients were rechecked in different places or other hospitals, and the information could not be collected completely and accurately. This resulted in a small sample size. Therefore, the results need to be interpreted carefully. Even so, this study still reflects the possibility that the NLR and PLR can be used as biological indicators to predict the prognosis of patients with cervical cancer.

Conclusions

The PLR, past diabetes, FIGO stage, and pathology type before radiotherapy were independent risk factors that influenced OS. Therefore, the NLR and PLR are important indicators that predict the prognosis of patients with cervical cancer.

Declarations

ACKNOWLEDGMENTS

The authors wish to acknowledge the contributions of the Department of Radiotherapy & Oncology at the Second Affiliated Hospital of Soochow University.

DISCLOSURE STATEMENT

There are no competing financial interests.

CONSENT FOR PUBLICATION

Our manuscript does not contain data from any individual person

FUNDING INFORMATION

1. Jiangsu Provincial Key Project (BL2018657).

2. Suzhou Special Project in Diagnosis and Treatment for Common Diseases (LCZX202005).

ETHICAL APPROVAL STATEMENT
Data are collected from The Second Affiliated Hospital of Soochow University and are devoid of any personal identifiable information.

**DATA AVAILABILITY STATEMENT**

The data that support the findings of this study are available from the corresponding author upon reasonable request.

**AUTHORS' CONTRIBUTIONS**

Ruizhe Xu, Haiyan Lu, and Qi Guo conceived the study, contributed to the study design, assisted with analysis, and wrote the first draft of the manuscript. Jianjun Qian, Qiuhong Fan, and Peifeng Zhao contributed to data preparation and analysis. Ye Tian contributed to the interpretation of the results and finalization of the report and reviewed and approved of the manuscript before submission. All authors agreed with the decision to submit.

**References**

1. Kagabu M, Nagasawa T, Sato C, Fukagawa Y, Kawamura H, Tomabechi H, Takemoto S, Shoji T, Baba T (2020). Immunotherapy for Uterine Cervical Cancer Using Checkpoint Inhibitors: Future Directions. International journal of molecular sciences 21(7):E2335.

2. Hull R, Mbele M, Mkhafola T, Hicks C, Wang SM, Reis RM, Mehrotra R, Mkhize-Kwitshana Z, Kibiki G, Bates DO, Dlamini Z (2020). Cervical cancer in low and middle-income countries. Oncology letters 20(3):2058–2074.

3. Ma J, Wang W, Shen J, Hou X, Lian X, Yan J, Sun S, Miao Z, Meng Q, Hu K, Zhang F (2020). Radiotherapy for Cervical Cancer in Patients with Systemic Lupus Erythematosus. Cancer management and research 12:8675–8683.

4. Matsuo K, Machida H, Mandelbaum RS, Konishi I, Mikami M (2019). Validation of the 2018 FIGO cervical cancer staging system. Gynecologic oncology 152(1):87–93.

5. Merz J, Bossart M, Bamberg F, Eisenblaetter M (2020). Revised FIGO Staging for Cervical Cancer - A New Role for MRI. RoFo: Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin 192(10):937-944.

6. Gai J, Wang X, Meng Y, Xu Z, Kou M, Liu Y (2019). Clinicopathological factors influencing the prognosis of cervical cancer [J]. Journal of B.U.ON.: official journal of the Balkan Union of Oncology 24(1):291–295.

7. Wang D, Bai N, Hu X, OuYang XW, Yao L, Tao Y, Wang Z (2019). Preoperative inflammatory markers of NLR and PLR as indicators of poor prognosis in resectable HCC [J]. PeerJ 7:e7132.

8. Hirahara T, Arigami T, Yanagita S, Matsushita D, Uchikado Y, Kita Y, Mori S, Sasaki K, Omoto I, Kurahara H, Maemura K, Okubo K, Uenosono Y, Ishigami S, Natsugoe S (2019). Combined neutrophil-
lymphocyte ratio and platelet-lymphocyte ratio predicts chemotherapy response and prognosis in patients with advanced gastric cancer. BMC cancer 19(1):672.

9. Chao B, Ju X, Zhang L, Xu X, Zhao Y (2020). A Novel Prognostic Marker Systemic Inflammation Response Index (SIRI) for Operable Cervical Cancer Patients. Frontiers in oncology 10:766.

10. Pavan A, Calvetti L, Dal Maso A, Attili I, Del Bianco P, Pasello G, Guarneri V, Aprile G, Conte P, Bonanno L (2019). Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors. The oncologist 24(8):1128-1136.

11. Abu-Shawer O, Abu-Shawer M, Haimour A, Alhouri A, Alkhatib AA, Abki M, Alqaisi O, Hamdan O, Alsaqri R, Ismail S, Altamimi T, Al-Hussaini M (2019). Hematologic markers of distant metastases in gastric cancer. Journal of gastrointestinal oncology 10(3):529–536.

12. Zhang Y, Liu X, Xu M, Chen K, Li S, Guan G (2020). Prognostic value of pretreatment systemic inflammatory markers in patients with locally advanced rectal cancer following neoadjuvant chemoradiotherapy. Scientific reports 10(1):8017.

13. Iwai N, Okuda T, Sakagami J, Harada T, Ohara T, Taniguchi M, Sakai H, Oka K, Hara T, Tsuji T, Komaki T, Kagawa K, Yasuda H, Naito Y, Itoh Y (2020). Neutrophil to lymphocyte ratio predicts prognosis in unresectable pancreatic cancer. Scientific reports 10(1):18758.

14. Wright JD, Matsuo K, Huang Y, Tergas AI, Hou JY, Khoury-Collado F, St Clair CM, Ananth CV, Neugut AI, Hershman DL (2019). Prognostic Performance of the 2018 International Federation of Gynecology and Obstetrics Cervical Cancer Staging Guidelines. Obstetrics and gynecology 134(1):49–57.

15. Yan DD, Tang Q, Chen JH, Tu YQ, Lv XJ (2019). Prognostic value of the 2018 FIGO staging system for cervical cancer patients with surgical risk factors. Cancer management and research 11:5473–5480.

16. Prabawa IPY, Bhargah A, Liwang F, Tandio DA, Tandio AL, Lestari AAW, Budiana ING, Manuaba IBAP (2019). Pretreatment Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte Ratio (PLR) as a Predictive Value of Hematological Markers in Cervical Cancer. Asian Pacific journal of cancer prevention: APJCP 20(3):863–868.

17. Lu Z, Yan W, Liang J, Yu M, Liu J, Hao J, Wan Q, Liu J, Luo C, Chen Y (2020). Nomogram Based on Systemic Immune-Inflammation Index to Predict Survival of Tongue Cancer Patients Who Underwent Cervical Dissection. Frontiers in oncology 10:341.

18. Zhang Y, Wang L, Liu Y, Wang S, Shang P, Gao Y, Chen X (2014). Preoperative neutrophil-lymphocyte ratio before platelet-lymphocyte ratio predicts clinical outcome in patients with cervical cancer treated with initial radical surgery [J]. International journal of gynecological cancer: official journal of the International Gynecological Cancer Society 24(7):1319–1325.

Figures
Figure 1

Overall survival curves of 172 patients with cervical cancer

Figure 2
ROC curves for the NLR (A) and PLR (B) before radiotherapy in 127 patients with cervical cancer

![ROC curves (A) and (B)]

Figure 3

Survival curves of 127 patients with cervical cancer grouped according to the NLR and PLR before radiotherapy. Survival curves comparing patients in the high and low NLR groups (A) and the high and low PLR groups (B) are shown. NLR, neutrophil to lymphocyte ratio; PLR, platelet to lymphocyte ratio.

![Box diagrams (A) and (B)]

Figure 4

Box diagrams of the peripheral blood NLR and FIGO stages in 127 patients with cervical cancer. NLR, neutrophil to lymphocyte ratio; FIGO, International Federation of Gynecology and Obstetrics.